製品番号: HY-N0631

Cornuside

(別名: コルヌシド)

7 Cited Publications

カスタマーレビュー

Based on 7 publication(s) in Google Scholar

Cornuside is an iridoid glycoside with anti-allergic, anti-inflammatory, and neuroprotective activities. Cornuside exerts anti-allergic activity by downregulating the p38 MAPK, JNK, and NF-κB signaling pathways, and inhibits IgE-mediated histamine release from mast cells. Cornuside improves cognitive impairment in mice by inhibiting BACE1 activity (IC₅₀ = 55.84 μg/mL) and enhancing ChAT activity. Cornuside inhibits LPS (HY-D1056)-induced inflammatory mediators, including iNOS, COX-2, PGE2, TNF-α, IL-6, and IL-1β, by suppressing NF-κB activation.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.99%
CAS 番号: 131189-57-6
分子式: C₂₄H₃₀O₁₄
分子量:542.49

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Cornuside 構造式

CAS 番号: 131189-57-6

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
化学情報
Publications (7)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target^[2]^[3]^[1]

p38 MAP kinase

NF-κB

JNK1

JNK2

AChE

BChE

iNOS

IL-6

IL-1β

COX-2

p38 MAPK アイソフォーム固有の製品をすべて表示 :

NF-κB アイソフォーム固有の製品をすべて表示 :

JNK アイソフォーム固有の製品をすべて表示 :

Cholinesterase (ChE) アイソフォーム固有の製品をすべて表示 :

AChE
BChE

Acyltransferase アイソフォーム固有の製品をすべて表示 :

NO Synthase アイソフォーム固有の製品をすべて表示 :

Interleukin Related アイソフォーム固有の製品をすべて表示 :

TNF Receptor アイソフォーム固有の製品をすべて表示 :

Prostaglandin Receptor アイソフォーム固有の製品をすべて表示 :

ERK アイソフォーム固有の製品をすべて表示 :

COX アイソフォーム固有の製品をすべて表示 :

体外実験

Cornuside exhibits free radical scavenging activity in a cell-free DPPH assay with an IC₅₀ of 20 μM^[1].
Cornuside protects SH-SY5Y cells from H₂O₂-induced damage by enhancing endogenous antioxidant defense systems^[1].
Cornuside (3-30 μM; 30 min) dose-dependently inhibits anti-DNP IgE-mediated histamine release from rat peritoneal mast cells, with significant effects at 10 and 30 μM^[2].
Cornuside (3-30 μM; 4 h) dose-dependently inhibits the production and secretion of TNF-α and IL-6 by PMA/A23187-stimulated human mast cells (HMC-1), with significant effects at 10 and 30 μM^[2].
Cornuside (3-30 μM; 1 h pre-incubation, 18 h LPS stimulation) dose-dependently inhibits LPS-induced nitric oxide production in RAW 264.7 cells, with maximum inhibition of 67.6% at 30 μM after 18 hours of LPS stimulation^[3].
Cornuside (3-30 μM; 1 h pre-incubation, 1 h LPS stimulation) dose-dependently inhibits LPS-induced nuclear translocation of the NF-κB p65 subunit in RAW 264.7 cells after 1 hour of LPS stimulation, with maximum inhibition at 30 μM^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:

human mast cells (HMC-1)
Concentration:

3, 10 and 30 μM
Incubation Time:

4 h (during PMA/A23187 stimulation)
Result:

Inhibited protein expression and secretion of TNF-α and IL-6 in a dose-dependent manner, with significant inhibition observed at 10 μM and 30 μM.\n
Inhibited the activation of p38 and JNK in a dose-dependent manner.
Reduced NF-κB p65 levels in the nucleus while increasing NF-κB p65 levels in the cytosol of PMA/A23187-stimulated HMC-1 cells.

ELISA Assay^[3]

Cell Line:

LPS-stimulated RAW 264.7 macrophage cell line
Concentration:

3, 10, 30 μM
Incubation Time:

1 h pre-incubation, followed by 18 h incubation with LPS
Result:

Significantly attenuated LPS-induced PGE2 production in a dose-dependent manner.

Western Blot Analysis^[3]

Cell Line:

LPS-stimulated RAW 264.7 macrophage cell line
Concentration:

3, 10, 30 μM
Incubation Time:

1 h pre-incubation, followed by 18 h incubation with LPS
Result:

Concentration-dependently suppressed LPS-induced protein expressions of iNOS and COX-2.

RT-PCR^[3]

Cell Line:

LPS-stimulated RAW 264.7 macrophage cell line
Concentration:

3, 10, 30 μM
Incubation Time:

1 h pre-incubation, followed by 6 h incubation with LPS
Result:

Concentration-dependently suppressed LPS-induced mRNA expressions of iNOS and COX-2, with levels correlated to protein expression changes.

Western Blot Analysis^[3]

Cell Line:

LPS-stimulated RAW 264.7 macrophage cell line
Concentration:

3, 10, 30 μM
Incubation Time:

1 h pre-incubation, followed by 1 h incubation with LPS
Result:

Dose-dependently inhibited LPS-induced translocation of the p65 subunit of NF-κB from the cytosol to the nucleus.\n
Increased cytoplasmic p65 levels to 80% of vehicle control and decreased nuclear p65 levels to 30% of LPS-only control at 30 μM.
Significantly blocked LPS-stimulated phosphorylation and degradation of IkB-α in a dose-dependent manner.\n
Reduced p-IkB-α levels to 20% of LPS-only control and restored IkB-α levels to 90-100% of vehicle control at 10 and 30 μM.\nSuppressed LPS-stimulated phosphorylations of ERK1/2, p38, and JNK1/2 in a concentration-dependent manner.\n
Reduced p-ERK1/2 levels to 40%, p-p38 levels to 10-15%, and p-JNK1/2 levels to 10-15% of LPS-only control at 30 μM.\n
Left non-phosphorylated ERK1/2, p38, and JNK1/2 expression unaffected.

体内実験

Cornuside (3-30 mg/kg; p.o.; daily administration for 15 consecutive days) ameliorates scopolamine (HY-N0296)-induced cognitive impairment in mice^[1].
Cornuside (50-200 mg/kg; p.o.; single administration) dose-dependently inhibits passive cutaneous anaphylaxis in mice and rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

ICR mice (male, 20 g, scopolamine-induced amnesia)^[1]
Dosage:

3 mg/kg; 10 mg/kg; 30 mg/kg
Administration:

p.o.; daily; day 4 to day 19
Result:

Significantly improved the learning and memory impairments of mice in the Scopolamine model in water maze, dark avoidance and jumping platform experiments.

Animal Model:

Male Sprague-Dawley and Institute of Cancer Research mice^[2]
Dosage:

50 mg/kg; 100 mg/kg; 200 mg/kg
Administration:

p.o.; single dose 1 hour before antigen challenge
Result:

Produced dose-dependent inhibition of passive cutaneous anaphylaxis.

化学情報

CAS 番号 131189-57-6
性状 Solid
分子量 542.49
分子式 C₂₄H₃₀O₁₄
Color White to off-white
SMILES

O=C(C1=CC(O)=C(O)C(O)=C1)OCCC(C(C(OC)=O)=COC2OC(C(C(O)C3O)O)OC3CO)C2C=C
別名

コルヌシド
Structure Classification
- Terpenoids
- Iridoids
- Phenols
- Polyphenols
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (7)

All

Sort by:

Journal Impact Factor

Phytomedicine

Cornuside improves murine autoimmune hepatitis through inhibition of inflammatory responses. [Abstract]

2023 Nov:120:155077. PMID: 37716032
Free Radic Biol Med

Cornuside alleviates microglia-mediated neuroinflammation to ameliorate chronic neuropathic pain-induced cognitive impairment via the Nrf2/Sirt3 signaling pathway. [Abstract]

2026 Jun:249:292-307. PMID: 41831801
Drug Des Devel Ther

The Natural Compound Cornuside Protects Against Acute Liver Failure Induced by Lipopolysaccharide and D-Galactosamine. [Abstract]

2026 Jun 3:20:601517. PMID: 42261449
Cells

Identification of Natural Compounds Triggering MRGPRX2-Mediated Calcium Flux and Degranulation in RBL-2H3 Cells. [Abstract]

2026 Feb 3;15(3):287. PMID: 41677650
Int Immunopharmacol

Cornuside alleviates psoriasis-like skin lesions in mice by relieving inflammatory effects. [Abstract]

2024 Jun 15:134:112183. PMID: 38705031
Naunyn Schmiedebergs Arch Pharmacol

Inhibitory effects of cornuside on human liver cytochrome P450 enzymes. [Abstract]

2025 Feb 13. PMID: 39939490
Tohoku J Exp Med

Cornuside Ameliorates Diabetic Nephropathy Possibly by Regulating Angiogenesis and MAPK Signaling. [Abstract]

2025 May 28;266(1):87-95. PMID: 39443135

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (184.34 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8434 mL

9.2168 mL

18.4335 mL

5 mM

0.3687 mL

1.8434 mL

3.6867 mL

10 mM

0.1843 mL

0.9217 mL

1.8434 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (285 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Wang ZX, et al. Cornuside ameliorates cognitive impairments in scopolamine induced AD mice: Involvement of neurotransmitter and oxidative stress. J Ethnopharmacol. 2022;293:115252. [Content Brief]

[2]. Li L, et al. Cornuside inhibits mast cell-mediated allergic response by down-regulating MAPK and NF-κB signaling pathways. Biochem Biophys Res Commun. 2016;473(2):408-414. [Content Brief]

[3]. Choi YH, et al. Cornuside suppresses lipopolysaccharide-induced inflammatory mediators by inhibiting nuclear factor-kappa B activation in RAW 264.7 macrophages. Biol Pharm Bull. 2011;34(7):959-966. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8434 mL	9.2168 mL	18.4335 mL	46.0838 mL
	5 mM	0.3687 mL	1.8434 mL	3.6867 mL	9.2168 mL
	10 mM	0.1843 mL	0.9217 mL	1.8434 mL	4.6084 mL
	15 mM	0.1229 mL	0.6145 mL	1.2289 mL	3.0723 mL
	20 mM	0.0922 mL	0.4608 mL	0.9217 mL	2.3042 mL
	25 mM	0.0737 mL	0.3687 mL	0.7373 mL	1.8434 mL
	30 mM	0.0614 mL	0.3072 mL	0.6145 mL	1.5361 mL
	40 mM	0.0461 mL	0.2304 mL	0.4608 mL	1.1521 mL
	50 mM	0.0369 mL	0.1843 mL	0.3687 mL	0.9217 mL
	60 mM	0.0307 mL	0.1536 mL	0.3072 mL	0.7681 mL
	80 mM	0.0230 mL	0.1152 mL	0.2304 mL	0.5760 mL
	100 mM	0.0184 mL	0.0922 mL	0.1843 mL	0.4608 mL

Cornuside

7 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Cornuside

Apoptosis Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

Neuronal Signaling Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Phenols Library

Pyroptosis Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

MedChemExpress（MCE）の使用を引用している文献 Cornuside

p38 MAPK アイソフォーム固有の製品をすべて表示

NF-κB アイソフォーム固有の製品をすべて表示